teva-spironolactone/hctz tablet
teva canada limited - spironolactone; hydrochlorothiazide - tablet - 50mg; 50mg - spironolactone 50mg; hydrochlorothiazide 50mg - mineralocorticoid (aldosterone) receptor antagonists
spironolactone- spironolactone tablet
unit dose services - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi
spironolactone- spironolactone tablet, film coated
unit dose services - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 100 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi
spironolactone teva 100 mg
teva israel ltd - spironolactone - tablets - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.
spironolactone tablet
blenheim pharmacal, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: - establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. - short-term preoperative treatment of patients with primary hyperaldosteronism. short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edema
spironolactone tablet
state of florida doh central pharmacy - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: - establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. - short-term preoperative treatment of patients with primary hyperaldosteronism. short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edema
spironolactone tablet, film coated
rebel distributors corp - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptionally high in
spironolactone tablet
nucare pharmaceuticals, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi
spironolactone and hydrochlorothiazide tablet
physicians total care, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. the treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. the treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. aldosterone levels may be exceptionally high in this condition. spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. for nephrotic patients when treatment of the und
spironolactone- spironolactone tablet, film coated
lake erie medical dba quality care products llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets, usp are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptiona